Carrier Is A Saccharide Patents (Class 530/813)
-
Patent number: 6043067Abstract: In a vertical down-flow fluid bed reactor, suspended particles in liquid proximal to an inlet in an uppermost part of the reactor are agitated to form a downward extending turbulent zone having vigorously moving particles and a non-turbulent zone distal to the inlet having essentially stationary particles in liquid below and adjoining the turbulent zone. In a vertical up-flow fluid bed reactor, an upward extending turbulent zone is formed proximal to an inlet in a lowermost part of the reactor and the non-turbulent zone is above the turbulent zone. The downward or upward extend of the turbulent zone is determined by the degree of agitation. The particles may contain an active substance and be in the form of a conglomerate of base particles having a desired density to control floatation or sedimentation. Particles in the turbulent and non-turbulent zones may be different such as having different specific gravities.Type: GrantFiled: January 8, 1998Date of Patent: March 28, 2000Assignee: Upfront Chromatography A/SInventors: Allan Otto Fog Lihme, Claus Schafer Nielsen, Thorkild Christian B.o slashed.g-Hansen
-
Patent number: 6028170Abstract: A tyrosine-substituted hirudin analog has antithrombogenic activity. Further simultaneous reaction at native tyrosine residues is prevented by mutation at those sites to encode nonreactive amino acids. Several novel strategies for coupling the hirudin analog to solid surfaces while simultaneously conserving antithrombogenic activity are disclosed.Type: GrantFiled: May 18, 1998Date of Patent: February 22, 2000Assignee: Baxter International Inc.Inventors: Cecilia S. L. Ku, Richard Johnson, Julian Breillatt
-
Patent number: 6020175Abstract: Multiple layered functional thin films fixed on a solid support are provided which comprise multiple layers of functional molecules (such as enzymes and other proteins, pigments and dyes) admixed with polymer ions in combination with multiple layers of polymer ions without the functional molecules. The films are prepared by immersing a solid support having an electric charge in an admixed polymer ion-functional molecule solution having a net electric charge opposite to that of the solid support followed by immersing the solid support in a polymer ion solution having a net electric charge opposite to that of the admixed polymer ion-functional molecule solution, and repeating at least once the immersings of the solid support in the solutions.Type: GrantFiled: September 10, 1997Date of Patent: February 1, 2000Assignee: Japan Science and Technology CorporationInventors: Mitsuhiko Onda, Yuri Lvov, Katsuhiko Ariga, Toyoki Kunitake
-
Patent number: 6010867Abstract: The present invention relates to a reagent for biomaterials assay of (fluorescent dye).sub.n --avidin--a compound having a plurality of reactive groups--a biomaterial, or a reagent in which avidin is bound to a compound having a plurality of reactive groups through biotin in the above, a method for preparing it, a plastic fiber optics necessary for utilizing this, an assaying device having a sensing portion utilizing this fiber optics and an assaying method of biomaterials by use of this reagent and device. The assay method can be used for immunoassay of biomaterials such as antigens, enzymes contained in extremely minute amounts in blood or body fluid in medical diagnosis, and improves detectable sensitivity to a great extent.Type: GrantFiled: June 2, 1997Date of Patent: January 4, 2000Assignee: Ibiden Co., Ltd.Inventors: Takeshi Kobayashi, Hiroyuki Honda, Ken-ichi Shimada
-
Patent number: 5993825Abstract: This invention relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type II which are covalently linked to protein. This invention further relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type V which are covalently linked to protein. This invention also relates to vaccines and methods of immunizing mammals, including humans against infection by Group B streptococcus type II (GBS II) and/or Group B streptococcus type V (GBS V). Multivalent vaccines comprising the conjugate molecules of this invention and antigens to other pathogenic bacteria are also claimed.Type: GrantFiled: February 13, 1998Date of Patent: November 30, 1999Assignees: National Research Council of Canada, Brigham and Women's Hospital, Inc.Inventors: Harold J. Jennings, Dennis L. Kasper
-
Patent number: 5985825Abstract: Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglobin-based oxygen carrier, while the non-oxygen carrying plasma expander my consist of an oncotic colloid-like starch.Type: GrantFiled: September 29, 1998Date of Patent: November 16, 1999Assignee: The Regents of the University of CaliforniaInventors: Robert M. Winslow, Marcos Intaglietta
-
Patent number: 5968794Abstract: A biodegradable particulate vector for transporting biologically active molecules is prepared containing a nucleus formed of a cross-linked polysaccharide or oligosaccharide matrix having grafted ionic ligands, a layer of fatty acid compounds covalently bonded to the nucleus and a layer of phospholipids hydrophobically bonded to the layer of fatty acid compounds. Dextran, cellulose or starch may be cross-linked with epichlorohydrin to form a cross-linked polysaccharide matrix. Ionic ligands may be grafted using an acidic compound such as succinic acid, phosphoric acid or phosphorous oxychloride, or a basic compound such as choline, hydroxycholine, 2-(dimethylamino)ethanol or 2-(dimethylamino) ethylamine fastened onto the grafted acidic compound. Phosphoric acid or phosphorous oxychloride in one step provide both cross-linking and ionic ligands. Co-cross-linking can be obtained using a protein such as keratin, collagen or elastase.Type: GrantFiled: January 23, 1998Date of Patent: October 19, 1999Assignee: Biovector Therapeutics S.A.Inventors: Daniel Samain, Ignacio De Miguel, Jaouad Meniali, Karim Ioualalen, Li Ding, Monique Cervilla, Valerie Rieumajou, Pascal Delrieu, Laurent Imbertie
-
Patent number: 5969040Abstract: Conjugates containing a substance with coagulant activity, such as recombinant Factor IX, non-antigenic polymers, such as poly(ethylene glycol), are disclosed. Also disclosed are methods of forming the novel conjugates of this invention.Type: GrantFiled: December 13, 1996Date of Patent: October 19, 1999Inventors: Terrence W. Hallahan, Carl W. Gilbert
-
Patent number: 5952473Abstract: The invention provides an immobilised oligopeptide for detecting protein prenylation consisting of an oligopeptide containing the amino acid sequence Xad-Xac-Xab-Xaa-OH at its carboxyl-terminus, at least one of Xaa, Xab, Xac and Xad representing cysteine (Cys), said sequence being capable of acting as a substrate for a prenyl transferase catalysing protein prenylation, and being bonded to a solid carrier, preferably at its amino-terminus. The invention further provides a kit for detecting protein prenylation comprising a first immobilised oligopeptide as mentioned above and a second immobilised oligopeptide which differs from said first immobilised oligopeptide in that the cysteine residue is substituted by another amino acid. Also provided are antibodies against the prenylated oligopeptides.Type: GrantFiled: October 16, 1997Date of Patent: September 14, 1999Inventors: Louis Hartog Cohen, Willem Nieuwenhuizen
-
Patent number: 5942406Abstract: Compositions and methods for avidin immobilized on an inert support material, e.g., agarose, are disclosed. The compositions have high activity levels of avidin and may further include a bulking agent, e.g., maltose, and a protectant to maintain the stability and integrity of the avidin agarose during lyophilization and terminal sterilization processes. A dry composition, and wet compositions such as a gel, slurry or suspension having avidin immobilized on an inert support material are disclosed. The dry composition has at least 1000 biotin binding units of activity, and the wet compositions have at least 50 units of binding activity. These compositions have applicability in any instance where avidin agarose and/or the avidin/biotin technology are useful. In particular, the present compositions are useful in an enzyme capture system to prepare fibrin monomer useful for fibrin sealants.Type: GrantFiled: August 1, 1997Date of Patent: August 24, 1999Assignee: E. R. Squibb & Sons, Inc.Inventors: Steven James Burton, James C. Pearson, Peter A. D. Edwardson
-
Patent number: 5935940Abstract: Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.Type: GrantFiled: August 5, 1997Date of Patent: August 10, 1999Assignee: Trustees of the University of PennsylvaniaInventor: Paul B. Weisz
-
Patent number: 5919907Abstract: A method of preparing a novel, sterile, receptor rich-albumin molecule which utilizes the disinfecting properties of iodine by reacting an iodine donating material or solution with a pure preparation of albumin, and preferably subsequently removing the iodine. The resulting iodine has improved binding properties because the production method strips bacterial endotoxin and other previously bound substances from the albumin. The improved binding site capacity of the albumin product is advantageously used as an adjunct in removing toxins by means of exchange transfusions. Because iodine disinfects the albumin typical pasteurization and related additives are unnecessary.Type: GrantFiled: December 22, 1997Date of Patent: July 6, 1999Assignee: Shanbrom Technologies LLCInventor: Edward Shanbrom
-
Patent number: 5904922Abstract: Antivenoms to snake, spider, scorpion and jelly fish venoms are produced for treatment of humans and animals, and for analytical use. Polyvalent antivenoms are produced containing immunoglobulin which is greater than fifty percent venom reactive. Purified polyvalent antivenom is derived from a first polyvalent antivenom having two or more monovalent subpopulations, and purified such that greater than fifty percent of the monovalent subpopulations are recovered by weight. The antivenoms can be horse or avian such as chicken antivenom. Chicken antivenom is obtained using a whole venom that is not glutaraldehyde pretreated, and the antivenom contains yolk immunoglobulin. Antivenoms are purified with an antigen matrix containing a single whole venom or a plurality of whole venoms covalently attached to an insoluble support such as aldehyde-activated agarose. Preferably, the whole venoms forming the plurality of whole venoms are selected from the four whole venoms of C. atrox, B. atrox, C. adamanteus and C.Type: GrantFiled: May 16, 1995Date of Patent: May 18, 1999Assignee: Ophidian Pharmaceuticals, Inc.Inventor: Sean B. Carroll
-
Patent number: 5902799Abstract: Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.Type: GrantFiled: August 5, 1997Date of Patent: May 11, 1999Assignee: The Trustees of the University of PennsylvaniaInventors: Howard C. Herrmann, Elliot Barnathan, Paul B. Weisz
-
Patent number: 5858392Abstract: A supported polyionic hydrogel is prepared by impregnating a support matel with a solution of anionic polysaccharide and a solution of cationic polysaccharide where the anionic polysaccharide and cationic polysaccharide react with each other to form a polyionic hydrogel impregnated in the support material. The hydrogel may be dried such as by lyophilization. Preferably, the anionic polysaccharide is xanthan, dicarboxystarch or dicarboxycellulose and the cationic polysaccharide is chitosan. Especially preferred is a polyionic hydrogel formed from xanthan and chitosan. A paper material or a textile material can be used as the support material. A dry supported polyionic hydrogel can be formed as a bandage without active material incorporated therein. The supported polyionic hydrogel may be formed containing a biologically active material by having the active material in either polysaccharide solution or in another solution impregnated into the support material.Type: GrantFiled: February 26, 1997Date of Patent: January 12, 1999Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Israel Fiber Institute, State of Israel Ministry & TradeInventors: Severian Dumitriu, Hilda Guttmann, Itzhak Kahane
-
Patent number: 5843461Abstract: This invention relates to antigenic conjugate molecules comprising the capsular polysaccharide of Group B streptococcus type II which are covalently linked to protein. This invention also relates to vaccines and methods of immunizing mammals, including humans against infection by Group B streptococcus type II (GBS II). Multivalent vaccines comprising the conjugate molecules of this invention and antigens to other pathogenic bacteria are also claimed.Type: GrantFiled: August 22, 1997Date of Patent: December 1, 1998Assignees: Brigham and Women's Hospital, Inc., National Research Council of CanadaInventors: Harold J. Jennings, Dennis L. Kasper
-
Patent number: 5837808Abstract: A tyrosine-substituted hirudin analog has antithrombogenic activity. Further simultaneous reaction at native tyrosine residues is prevented by mutation at those sites to encode nonreactive amino acids. Several novel strategies for coupling the hirudin analog to solid surfaces while simultaneously conserving antithrombogenic activity are disclosed.Type: GrantFiled: June 19, 1995Date of Patent: November 17, 1998Assignee: Baxter International Inc.Inventors: Cecilia S. L. Ku, Richard Johnson, Julian P. Breillatt, Jr.
-
Patent number: 5817528Abstract: A method is provided for producing a sterile and pyrogen-free column containing coupled protein for use in removing a predetermined substance from the blood of a human subject. The method abrogates sterilization of the finished protein-containing product by providing sterile and pyrogen-free raw materials at each production step. The method provides a pathogen-free, purified solution of protein which binds to a predetermined substance in human blood such as LDL or immunoglobulin. Typically, the protein is anti-human LDL immunoglobulin or anti-human Ig immunoglobulin. The method also provides a sterile and pyrogen-free column matrix material such as an agarose which is chemically activated, either using CNBr and triethylamine or using 1,1'-carbonyldiimidazole.Type: GrantFiled: May 16, 1995Date of Patent: October 6, 1998Assignee: Therasorb Medizinische Systeme GmbHInventors: Wolfgang Bohm, Franz A. Bieber, Jutta Muller-Derlich, Alan Barclay, Reiner Spaethe, Michael Bernhard, Christine Kraus
-
Patent number: 5736371Abstract: A biodegradable particulate vector for transporting biologically active molecules is prepared containing a nucleus for containing a biologically active molecule, a first layer of fatty acid compounds covalently bonded to the nucleus and a second layer of phospholipids hydrophobically bonded to the first layer. The nucleus is between 10 nm and 10 .mu.m in size and is formed of a cross-linked polysaccharide or oligosaccharide matrix onto which ionic ligands are uniformly grafted. The cross-linked polysaccharide may be dextran, cellulose or starch cross-linked with epichlorohydrin. The ligand may be an acidic compound selected from succinic acid, phosphoric acid, citric acid, glycine, alanine, glutamic acid and aspartic acid, or a basic compound such as choline, hydroxycholine, 2-(dimethylamino)ethanol or 2-(dimethylamino)ethylamine fastened onto the matrix via the acidic compound. The polysaccharide or oligosaccharide may be co-cross-linked with a protein such as keratin/collagen or elastase.Type: GrantFiled: May 16, 1994Date of Patent: April 7, 1998Assignee: A et S BiovecteursInventors: Daniel Samain, Ignacio De Miguel, Jaouad Meniali, Karim Ioualalen, Li Ding, Monique Cervilla, Valerie Rieumajou, Pascal Delrieu, Laurent Imbertie
-
Patent number: 5719031Abstract: This invention relates to polymers labeled with fluorescent dye to the point that significant fluorescence quenching occurs, such that degradation of the polymer results in fluorescence enhancement. The resulting fluorescence enhancement is useful for measuring the degradation of such polymers, for example as a result of enzymatic hydrolyis of a protein, carbohydrate, nucleic acid, or other natural or synthetic polymer.Type: GrantFiled: August 14, 1996Date of Patent: February 17, 1998Assignee: Molecular Probes, Inc.Inventors: Richard P. Haugland, Mingjie Zhou
-
Patent number: 5705368Abstract: The process comprises heat-treating a xanthan gum fermented broth, and consecutively treating the broth first with alkaline protease and then with lysozyme or in reverse order, and thereafter recovering xanthan gum from the treated broth. A clear aqueous solution of xanthan gum may be obtained without complex procedures.Type: GrantFiled: December 15, 1992Date of Patent: January 6, 1998Assignees: Shin-Etsu Chemical Co., Ltd., Shin-Etsu Bio, Inc.Inventors: Kanji Murofushi, Taira Homma, Shigehiro Nagura, Richard Armentrout
-
Patent number: 5658894Abstract: Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.Type: GrantFiled: November 23, 1994Date of Patent: August 19, 1997Assignee: The Trustees of the University of PennsylvaniaInventor: Paul B. Weisz
-
Patent number: 5648252Abstract: A supported polyionic hydrogel containing biologically active material is epared by impregnating into a porous support material a solution of anionic polysaccharide, a solution of cationic polysaccharide and a biologically active material. The anionic polysaccharide and the cationic polysaccharide react with each other to form a hydrogel containing the biologically active material. The hydrogel may be dried such as by lyophilization. The biologically active material can be in either polysaccharide solution or in another solution impregnated into the porous support material. A paper material or a textile material may be used as the porous support material. Preferably, the anionic polysaccharide is xanthan, dicarboxystarch or dicarboxycellulose and the cationic polysaccharide is chitosan. Especially preferred is a hydrogel formed from xanthan and chitosan.Type: GrantFiled: March 22, 1995Date of Patent: July 15, 1997Assignees: Israel Fiber Institute State of Israel Ministry of Industry and Trade, Yissum Research Development Company of the University of JerusalemInventors: Severian Dumitriu, Itzhak Kahane, Hilda Guttmann
-
Patent number: 5563056Abstract: A chemical specie is immobilized in a three dimensional, crosslinked matrix by bringing together in covalent bonding proximity a desired chemical specie and a polymeric coupling compound such as a photoderivatized polymer having at least two latent photochemical reactive groups per molecule, each latent reactive group being capable when activated of covalently bonding to another coupling compound molecule or to the chemical specie. The chemical specie may be a protein, carbohydrate, nucleic acid or lipid, and desirably is free of latent reactive groups that are activated upon activation of the latent reactive groups of the coupling compound. The latent reactive groups are simultaneously activated to cause formation via covalent bonding of a three-dimensional molecular network in which molecules of the chemical specie are covalently bonded to molecules of the coupling compound, and molecules of the coupling compound are covalently bonded to each other.Type: GrantFiled: February 27, 1995Date of Patent: October 8, 1996Assignee: BSI CorporationInventors: Dale G. Swan, Mark W. Josephson, Melvin J. Swanson
-
Patent number: 5543332Abstract: Water soluble reagents are claimed, comprising a water-soluble polymeric carrier molecule having attached thereto more than one connecting moiety wherein the connecting moiety is derived from divinyl sulfone, and wherein each connecting moiety is attached to a reactive functional group on the polymeric molecule, and wherein the reagents are capable of reaction with a molecular species having a functional group which is reactive towards the terminal vinyl group of the more than one connecting moiety and the molecular species is selected from the group consisting of labelling species, marking species, and targeting species.Type: GrantFiled: November 8, 1991Date of Patent: August 6, 1996Assignee: Immunodex K/SInventors: Allan O. F. Lihme, Thomas Boenisch
-
Patent number: 5516766Abstract: Polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are disclosed. Compositions and methods for separating a molecular species, including but not limited to a biologically active protein, from a mixture, for the storage of protein factors and for the therapeutic biodelivery of protein factors which employ the polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are also disclosed.Type: GrantFiled: November 12, 1993Date of Patent: May 14, 1996Assignee: The Trustees of the University of PennsylvaniaInventors: Paul B. Weisz, Yuen W. Shing, Judah Folkman
-
Patent number: 5491083Abstract: Poly(fluoroalkyl) sugar reagents are prepared containing a sugar such as a monosaccharide or a disaccharide to which are bonded a plurality of fluoroalkyl anchor groups capable of attaching to a fluorocarbon surface, and either a reactive group capable of covalent coupling to a biomolecule such as an enzyme or a charged group to form an ion-exchanger or a non-ionic group to give a neutral fluorosurfactant. A spacer may be between the reactive group and the sugar. The poly(fluoroalkyl) sugar reagents are strongly adsorbed onto fluorocarbon surfaces to provide supports for such applications as separation and immobilization of biomolecules such as enzymes, carrying out heterogeneous diagnostic assays, and preparation of biosensors.Type: GrantFiled: October 5, 1994Date of Patent: February 13, 1996Assignee: E. I. Du Pont de Nemours and CompanyInventors: Rene Arentzen, Prabhakar K. Jadhav, Robert K. Kobos, Bruce E. Smart
-
Patent number: 5478576Abstract: A substantially purified arabinogalactan, its degradative products and selected modifications thereof have been found to act as carriers for delivering therapeutic agent to cell receptors capable of receptor mediated endocytosis (RME). The arabinogalactan and its degrative products once derivatived are capable of forming a complex between the therapeutic agent and the polysaccharide such that the complex retains the ability to recognize and bind to the RME receptor.Type: GrantFiled: June 17, 1992Date of Patent: December 26, 1995Assignee: Advanced Magnetics, Inc.Inventors: Chu Jung, Philip Enriquez, Stephen Palmacci, Lee Josephson, Jerome M. Lewis
-
Patent number: 5466681Abstract: A variety of conjugates useful for the treatment of infections due to pathogenic microorganisms are provided. The conjugates comprise at least one agent coupled to a receptor which binds a microorganism. Suitable agents include anti-infectives, such as antibiotics and synthetic drugs. The present invention also provides methods for treating infections in warm-blooded animals due to pathogenic microorganisms.Type: GrantFiled: January 12, 1994Date of Patent: November 14, 1995Assignee: MicroCarb, Inc.Inventors: Howard C. Krivan, A. Lennart I. Blomberg
-
Patent number: 5466609Abstract: The invention relates generally to colloidal particle having a core material and a gelatin/aminodextran coating with pendent functional groups attached thereto. Biological substances or molecules, especially monoclonal antibodies, may be attached to said particles. The monoclonal antibody containing particles are useful in a variety of positive and negative biological assays.Type: GrantFiled: October 29, 1992Date of Patent: November 14, 1995Assignee: Coulter CorporationInventors: Olavi Siiman, Alexander Burshteyn, Ravinder K. Gupta
-
Patent number: 5456922Abstract: The present invention relates to compositions of water dispersible and water soluble carbohydrate polymers and biologically active macromolecules of growth hormones, somatomedins, growth factors, and other biologically active fragments which are suitable for parenteral administration. The present invention also relates to a method for increasing and for maintaining increased levels of growth hormone in the blood of treated animals for extended periods of time, increasing weight gains in animals, and increasing milk production of lactating animals by the administration of the compositions of the invention.Type: GrantFiled: August 18, 1993Date of Patent: October 10, 1995Assignee: American Cyanamid CompanyInventors: Susan M. Cady, Richard Fishbein, Ulf Schroder, Hakan Eriksson, Brenda L. Probasco
-
Patent number: 5449757Abstract: Mammalian adipogenic factors, including purified proteins or glycoproteins, capable of inducing the adipose differentiation of adipogenic cells are disclosed, as are antibodies to such proteins, DNA encoding the proteins and host cells expressing the proteins. A method for determining the susceptibility of a subject to obesity by measuring the levels of one or more adipogenic factors in a biological fluid or tissue extract is also disclosed, as is a method for evaluating an anti-obesity drug which comprises contacting the drug with cells capable of producing one or more adipogenic factors and measuring the amount of the factors produced.Type: GrantFiled: March 22, 1994Date of Patent: September 12, 1995Assignee: W. Alton Jones Cell Science CenterInventor: Ginette Serrero
-
Patent number: 5443976Abstract: Antivenoms to snake, spider, scorpion and jelly fish venoms are produced for the treatment of humans and animals, and for analytical use. The antivenom is purified with an antigen matrix containing a single whole venom or a plurality of whole venoms covalently attached to an insoluble support such as aldehyde-activated agarose. Preferably, the whole venoms forming the plurality of whole venoms are selected from the four whole venoms from C. atrox, B. atrox, C. adamanteus and C. durissus terrificus. A combination of immobilized C. atrox and C. durissus terrificus whole venoms can substantially purify antivenom reactive with all four venoms. The antivenom can be horse or avian such as chicken antivenom.Type: GrantFiled: July 14, 1994Date of Patent: August 22, 1995Inventor: Sean B. Carroll
-
Patent number: 5439829Abstract: A chelating agent is covalently bonded to a biologically active molecule such as an enzyme or antibody, the biologically active molecule is contacted with a support containing a bound transition metal ion whereby the metal ion is chelated by the chelating agent and the oxidation state of the metal ion is changed by treatment with an oxidizing or a reducing agent to provide a kinetically inert: oxidation state to immobilize the biologically active molecule on the support. The transition metal ion is preferably Co(II), Cr(II) or Ru(III) and the oxidation state of the metal ion is changed to Co(III), Cr(III) or Ru(II), respectively. The chelating agent can be iminodiacetic acid, nitrilotriacetic acid, terpyridine, bipyridine, triethylenetetraamine, biethylenetriamine, 1,4,7-triazacyclonane or a chelating peptide. Certain chelating agents can immobilize more than one biologically active molecule at a metal ion site on the support.Type: GrantFiled: January 24, 1992Date of Patent: August 8, 1995Assignees: Eli Lilly and Company, Hybritech IncorporatedInventors: Leslie D. Anderson, James A. Cook, Gary S. David, Susan M. Hochschwender, Mary S. Kasher, Michele C. Smith, Willem P. C. Stemmer
-
Patent number: 5384254Abstract: Poly(fluoroalkyl) sugar reagents are prepared containing a sugar such as a monosaccharide or a disaccharide to which are bonded a plurality of fluoroalkyl anchor groups capable of attaching to a fluorocarbon surface, and either a reactive group capable of covalent coupling to a biomolecule such as an enzyme or a charged group to form an ion-exchanger or a non-ionic group to give a neutral fluorosurfactant. A spacer may be between the reactive group and the sugar. The poly(fluoroalkyl) sugar reagents are strongly adsorbed onto fluorocarbon surfaces to provide supports for such applications as separation and immobilization of biomolecules such as enzymes, carrying out heterogeneous diagnostic assays, and preparation of biosensors.Type: GrantFiled: May 20, 1993Date of Patent: January 24, 1995Assignee: E. I. Du Pont de Nemours and CompanyInventors: Rene Arentzen, Prabhakar K. Jadhav, Robert K. Kobos, Bruce E. Smart
-
Patent number: 5372820Abstract: This granular material consists of a granular porous support bearing negative or positive charges, coated on its surface with a first layer of impregnation with a hydrophilic polymer bearing charges opposite to those of the support, the quantity of said charges present on said polymer being substantially equal to that of the charges present at the surface of the support; and another layer, bound to the first by irreversible chemical coupling, of another hydrophilic polymer which is functional, namely bearing groups endowing said functional hydrophilic polymer with a specific but reversible affinity for at least one biological substance. Among the applications of this material, there are mentioned the separation and purification of antithrombin III and coagulation factors (factors II, VII, VIII, IX, X), and separation of activated coagulation factors (activated factor II, activated factor IX, activated factor X) in solutions containing said non-activated factors.Type: GrantFiled: October 14, 1992Date of Patent: December 13, 1994Assignee: Therapeutiques Subtitutives Groupement D'Interet PublicInventors: Jacqueline Jozefonvicz nee Dorgebray, Xavier-Francois Santarelli, Daniel A. Muller
-
Patent number: 5362859Abstract: An affinity support having an improved capacity for binding target compounds. The support includes an immobilized modified ligand of increased molecular weight. The molecular weight of the ligand is increased via the action of condensation reagents or crosslinkers prior to immobilization. The affinity support is useful in affinity separations of proteins and other biomolecules from complex, biologically-derived fluids.Type: GrantFiled: July 27, 1992Date of Patent: November 8, 1994Assignee: Sepracor, Inc.Inventor: Stephen E. Zale
-
Patent number: 5342770Abstract: The present invention provides a conjugate in essentially pure form comprising a sugar linked to a protein through a peptide linker, wherein said sugar has a reducing terminal and is free of carboxyl groups, and wherein the reducing terminal of said sugar is linked to the peptide linker. The present invention further provides a conjugate in essentially pure form comprising a sugar linked to an enzyme through a peptide linker, wherein said sugar has a reducing terminal and is free of carboxyl groups, and wherein the reducing terminal of said sugar is linked to the peptide linker. The present invention additionally provides a conjugate in essentially pure form comprising a sugar linked to lysozyme through a peptide linker, wherein said sugar has a reducing terminal and is free of carboxyl groups, and wherein the reducing terminal of said sugar is linked to the peptide linker.Type: GrantFiled: May 11, 1993Date of Patent: August 30, 1994Assignee: Chisso CorporationInventor: Nobuyuki Yamasaki
-
Patent number: 5310885Abstract: The present invention provides a process for immobilizing a protein or protein containing substance. The material to be immobilized is aggregated, contacted in a liquid with a hydrophilic solid phase and the solid phase, after contact has taken place, is dried. The present invention is also concerned with the solid phase prepared by this process and with the use thereof for analytical determination.Type: GrantFiled: May 19, 1992Date of Patent: May 10, 1994Assignee: Boehringer Mannheim GmbHInventors: Josef Maier, Dieter Mangold, Reiner Schlipfenbacher
-
Patent number: 5268306Abstract: A specific binding pair is bound to an insoluble carrier for use in determining an analyte such as in an immunoassay. The carrier is coated with a first polymer containing a protein polymer having a molecular weight of at least about 20,000 and molecules of a first member of a specific binding pair. A second polymer containing a second member of the specific binding pair is bound to the first member on the carrier by binding of the first and second members of the specific binding pair. The first polymer is preferably more hydrophobic than the second polymer. The protein polymer can be prepared by cross-linking hydrophobic protein molecules of 10,000 to 700,000 molecular weight with a bifunctional or polyfunctional compound to obtain a protein polymer of 200,000 to 20,000,000 molecular weight. The second polymer can be the second member of the specific binding pair or the second member cross-linked with a linker or the second member cross-linked to a hydrophobic protein.Type: GrantFiled: December 23, 1991Date of Patent: December 7, 1993Assignee: Boehringer Mannheim GmbHInventors: Michael Berger, Arno Deger, Josef Maier
-
Patent number: 5268272Abstract: Complexes which contain at least one glycosyl-phosphatidylinositol protein and at least one cholanic acid derivative of the formula I ##STR1## are suitable, inter alia, in enzyme tests and as aids in chemical reactions; where R.sup.1 is --NH--CH.sub.2 --CH.sub.2 --SO.sub.3 or --NH--CH.sub.2 --COOH, R.sup.2 is NR.sup.3 R.sup.4 or --OR.sup.5 ; R.sup.3, R.sup.4 or R.sup.5 are a hydrogen atom, (C.sub.1 -C.sub.5)-alkyl, (C.sub.3 -C.sub.6)-cycloalkyl, substituted acetyl, halogen, succinyl, substituted benzyl or substituted benzoyl.Type: GrantFiled: February 25, 1993Date of Patent: December 7, 1993Assignee: Hoechst AktiengesellschaftInventors: Stefan Mullner, Gunter Muller
-
Patent number: 5266471Abstract: A modified solid carrier is used to covalently immobilize biomolecules such as proteins. The carrier is based on well-known matrix materials modified to have covalently bound functional groups of formula I ##STR1## that are suitable for covalent immobilization, where A is a spacer group; X is O, S, or NH and n is 0 or 1. The modified solid carrier is prepared by reacting ammonia with glycidyl groups of a carrier to form .alpha.-hydroxy-.beta.-amino groups, reacting these groups with 2,4,6-trichloro-s-triazine to form an N-triazinyl group-containing carrier, reacting this carrier with ammonia and reacting the resultant carrier with 2,4,6-trichloro-s-triazine.Type: GrantFiled: February 25, 1991Date of Patent: November 30, 1993Assignee: ROHMInventor: Stefan Schmitt
-
Patent number: 5266333Abstract: The present invention relates to compositions of water dispersible and water soluble carbohydrate polymers and biologically active macromolecules of growth hormones, somatomedins, growth factors, and other biologically active fragments which are suitable for parenteral administration. The present invention also relates to a method for increasing and for maintaining increased levels of growth hormone in the blood of treated animals for extended periods of time, increasing weight gains in animals, and increasing milk production of lactating animals by the administration of the compositions of the invention.Type: GrantFiled: August 30, 1989Date of Patent: November 30, 1993Assignee: American Cyanamid CompanyInventors: Susan M. Cady, Richard Fishbein, Ulf Schroder, Hakan Eriksson, Brenda L. Probasco
-
Patent number: 5266686Abstract: A process is described for isolating an enzyme-antibody conjugate, wherein the enzyme is horseradish peroxidase or alkaline phosphatase, from an aqueous mixture of said conjugate and unconjugated enzyme. The process involves contacting the mixture with a water insoluble stationary phase having the Ni.sup.+2 ion chelated thereto and binding said conjugate to the stationary phase. The phase containing bound conjugate is then washed to remove unbound enzyme. Thereafter the conjugate is eluted from the stationary phase and recovered in a form substantially free of the unconjugated enzyme.Type: GrantFiled: September 25, 1992Date of Patent: November 30, 1993Assignee: Pierce Chemical CompanyInventor: Keld Sorensen
-
Patent number: 5246698Abstract: Disclosed are biocompatible viscoelastic gel slurries formed from a polymeric gel, preferably a hyaluronan or a derivative thereof such as hylan swollen in an aqueous medium and a fluid phase which is an aqueous solution of a polymer which may also but not necessarily be a hyaluronan or derivative thereof. Also disclosed are methods of making such slurries, controlling their rheological properties and the uses thereof.Type: GrantFiled: December 20, 1991Date of Patent: September 21, 1993Assignee: Biomatrix, Inc.Inventors: Edward Leshchiner, Endre A. Balazs, Nancy E. Larsen, Adelya Leshchiner
-
Patent number: 5219926Abstract: A process for covalently bonding biopolymer, such as protein, to an organic polymer surface coated with hydrophilic nonionic polymer having groups reactive with the biopolymer and having a cloud point in the reaction medium that is at least 5.degree. C. above the temperature at which the coated organic polymer surface is to be used, which comprises reacting biopolymer with the surface in an aqueous reaction medium, at a temperature not less than 5.degree. C. below the cloud point; but not above a temperature at which the biopolymer is deleteriously affected, and preferably not above about 100.degree. C., the product comprises a biopolymer immobilized on a hydrophilic solid surface having a nonionic polymer and a hydrophilic layer, coupled thereto via biopolymer-reactive groups of the nonionic polymer, and accordingly has low spontaneous adsorption of proteins and other biopolymers through electrostatic attraction and/or hydrophobic interaction.Type: GrantFiled: September 13, 1991Date of Patent: June 15, 1993Assignee: Berol Nobel ABInventors: Bjorn Lindman, Martin Malmsten, Krister Holmberg, Carina Andren
-
Patent number: 5213898Abstract: Method for surface modifying substrates characterized in adsorbing on the surface of a solid substrate a polyamine of a high average molecular weight and cross-linking this with crotonaldehyde either simultaneously or by addition in separate steps to produce amino groups on the surface of the substrate, and optionally adsorbing one or several alternating layers of an anionic polysaccharide and of the said polyamine being cross-linked with crotonaldehyde, and optionally finally adsorbing the said polyamine, not cross-linked, to produce free primary amino groups by which chemical entities having a biological activity may be bound by covalent or ionic bonding.Type: GrantFiled: June 14, 1991Date of Patent: May 25, 1993Assignee: Norsk Hydro a.s.Inventors: Karl O. P. Larm, Lars A. Adolfsson, Kjell P. Olsson
-
Patent number: 5204451Abstract: The invention relates to a method of binding biologically active organic ligands to hydroxyl groups of polymeric carriers. The method involves bringing 4-fluorobenzenesulfonyl Chloride into reactive contact with the hydroxyl groups of polymeric carriers in such a manner to form sulfonate groups in place of the hydroxyl groups. The ligand is then brought into reactive contact with the hydroxyl groups of polymeric carriers to replace the sulfonate groups reacted with the organic ligand. The polymeric carrier containing the bound ligand can be used to isolate a biologically active material from a heterogeneous solution.Type: GrantFiled: August 13, 1990Date of Patent: April 20, 1993Assignee: Baxter International Inc.Inventor: Yu-An Chang
-
Patent number: 5183809Abstract: Polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are disclosed. Compositions and methods for separating a molecular species, including but not limited to a biologically active protein, from a mixture, for the storage of protein factors and for the therapeutic biodelivery of protein factors which employ the polyionic derivatives of cyclodextrin polymers and cyclodextrins immobilized on a solid surface are also disclosed.Type: GrantFiled: February 15, 1990Date of Patent: February 2, 1993Assignee: The Trustees of the University of Pennsylvania/Childrens Hospital CorporationInventors: Paul B. Weisz, Yuen W. Shing, Judah Folkman
-
Patent number: 5162503Abstract: Methods are provided for the purification of interleukin-2 (IL-2) from a wide variety of sources, including synthetic mixtures, culture medium conditioned by natural IL-2 producing cells, and mammalian and bacterial recombinant IL-2 expression systems. The methods of the invention employ IL-2 receptor-affinity adsorbents in which soluble IL-2 receptors have been immobilized on solid supports. Through the use of these affinity adsorbents, highly purified IL-2 can be produced in a single step from bacterial extracts or conditioned medium. The IL-2 thus purified is largely free of aggregated forms, which are often present when other purification methods are used.Type: GrantFiled: May 19, 1987Date of Patent: November 10, 1992Assignee: Hoffmann-La Roche, Inc.Inventors: Pascal Bailon, John E. Smart, David V. Weber